Carmelo Tibaldi
Lucca, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
Journal: Tumori
Published: December 16, 2024
Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Journal: Journal of clinical medicine
Published: April 16, 2024
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression.
Journal: Translational oncology
Published: July 14, 2023
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
Journal: Anti-cancer agents in medicinal chemistry
Published: November 16, 2020
Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance.
Journal: Cancers
Published: October 28, 2020
A reply to "Immune related adverse events and response to immunotherapy: focus on corticosteroids."
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 08, 2020
Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: January 10, 2020
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 12, 2019
Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
Journal: British journal of cancer
Published: June 08, 2018
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.
Journal: Oncotarget
Published: May 30, 2017
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Journal: World journal of clinical oncology
Published: February 13, 2017
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 31, 2017
Last Updated: 09/26/2026